Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:48Neutral
Price Target:
$16.50
▼(-47.01% Downside)
Action:Reiterated
Date:10/08/26
The score is held down primarily by pre-revenue financials with large losses and cash burn, plus clearly bearish technical momentum with the stock trading well below major moving averages. Corporate events are mixed but skew negative due to the Phase 3 primary-endpoint miss, while valuation remains difficult to support given ongoing losses and no dividend.
Positive Factors
Low Leverage and Expanded Asset Base
Extremely low debt relative to equity and substantial asset expansion provide a stronger funding base for continued clinical development. This reduces near-term dependence on lenders and preserves flexibility to allocate capital across trials, although it does not yet establish profitability.
Negative Factors
FURVENT Phase 3 Primary-Endpoint Miss
The pivotal failure is a material setback for firmonertinib in first-line EGFR exon 20 insertion NSCLC. Despite favorable secondary measures and safety, the result may complicate the U.S. development path and force a reassessment of the lead program.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Expanded Asset Base
Extremely low debt relative to equity and substantial asset expansion provide a stronger funding base for continued clinical development. This reduces near-term dependence on lenders and preserves flexibility to allocate capital across trials, although it does not yet establish profitability.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$824.92M
Dividend YieldN/A
Average Volume (3M)1.44M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth8.22%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.68
Shares Outstanding49,307,728
10 Day Avg. Volume3,207,774
30 Day Avg. Volume1,443,938
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.82
Forecast
1Y Price Target
$25.82Price Target Upside-17.09% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.24
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is ...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -163.74M | -166.31M | -80.49M | -69.33M | 0.00 | -51.61M |
| Net Income | -163.74M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | ||||||
| Total Assets | 394.72M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 373.12M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 351.00K | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 27.88M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 366.84M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -72.31M | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 262.15M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Negative
31.14
Price Trends
28.74
Negative
29.97
Negative
27.24
Negative
Market Momentum
-3.02
Positive
23.37
Positive
27.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Negative. The current price of 31.14 is above the 20-day moving average (MA) of 26.53, above the 50-day MA of 28.74, and above the 200-day MA of 27.24, indicating a bearish trend. The MACD of -3.02 indicates Positive momentum. The RSI at 23.37 is Positive, neither overbought nor oversold. The STOCH value of 27.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 93 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $942.98M | -3.15 | -207.18% | ― | -7.27% | -48.89% | |
56 Neutral | $758.92M | -3.41 | -467.49% | ― | 3995.74% | 24.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $242.50M | -1.44 | -215.23% | ― | 291.42% | 11.70% | |
48 Neutral | $824.92M | -4.55 | -50.26% | ― | ― | 8.22% | |
48 Neutral | $999.43M | -4.61 | -52.89% | ― | ― | 3.56% | |
45 Neutral | $249.93M | -1.07 | -87.95% | ― | -100.00% | 14.08% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
16.46
-4.44
-21.24%
VSTM
Verastem
8.25
-1.04
-11.19%
KURA
Kura Oncology
10.40
0.46
4.68%
ZNTL
Zentalis Pharmaceuticals
2.52
0.90
55.56%
CGEM
Cullinan Management
14.95
7.12
90.93%
PYXS
Pyxis Oncology
2.01
-1.44
-41.74%
ArriVent BioPharma, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint
Negative
Oct 6, 2026
On October 6, 2026, ArriVent reported that its global Phase 3 FURVENT trial of firmonertinib as a first-line monotherapy for EGFR exon 20 insertion mutant non-squamous NSCLC failed to meet its primary endpoint of progression-free survival by blind...
Business Operations and StrategyFinancial Disclosures
ArriVent inks China partnership for ARR-002 development
Positive
Aug 12, 2026
On August 11, 2026, ArriVent BioPharma entered into an exclusive collaboration and license agreement with Shanghai Allist Pharmaceuticals, granting Allist rights to research, develop, manufacture and commercialize ARR-002 in Greater China while re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.